Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Sandu Pharmaceuticals Ltd

    Sandu' is an ISO 9001:2000 certified group of companies established in 1899 specializing in manufacture and marketing of Ayurvedic medicines and is blessed with a rich heritage

  • No Image
    Sanjivani Parenteral Ltd

    Sanjivani Parenteral Ltd is a research-based, international pharmaceutical company established in 1997 .

  • No Image
    Sanofi India Ltd

    Sanofi India Limited in India provides medicines for the treatment of patients in several therapeutic areas: cardiology, thrombosis, oncology, diabetes, central nervous system,

  • No Image
    Satyam Metal Industries

    Satyam Metal Industries is engaged in wholesaling, supplying, and trading of a wide variety of sulphates & other inorganic salts. This range includes manganese sulphate, magnesi